Gradipore's loss slightly higher than expected
29 August, 2003 by Iain ScottSydney bioseparations specialist Gradipore (ASX:GDP) has reported an operating loss for 2002-03 of AUD$16.7 million, down from an $18.5 million loss the previous year but slightly higher than the figure forecast by the company in May.
Prima touts human trials hopes for vaccine tech
29 August, 2003 by Melissa TrudingerPrima Biomed subsidiary PanVax is planning to test its DCtag adjuvant technology with an existing marketed vaccine in human clinical trials, aiming to demonstrate enhanced immunogenicity of the re-engineered vaccine compared to existing formulations.
Cancer drug trials lift Progen losses
29 August, 2003 by Graeme O'NeillResearch and development costs -- including the expense of continuing clinical trials of its promising anti-cancer drug PI-88 -- have seen Brisbane drug-development company Progen Industries (ASX:PGL, NASDAQ:PGLAF) post a net operating loss of AUD$7.8 million to June 30.
Biota reports loss with silver lining
29 August, 2003 by Graeme O'NeillMelbourne-based drug-discovery company Biota Holdings Ltd (ASX:BTA) has reported a AUD$10.3 million loss for the year to June 30, but much of the loss was due to $9.8 million in expenses incurred by its new US subsidiary Biota Inc during its first full year of operation.
AGT presents new data on obesity
28 August, 2003 by Melissa TrudingerAGT Biosciences (ASX:AGT) has presented data on a new gene linked to obesity at the International Diabetes Federation Conference in Paris.
Antisense launches Phase I MS trials
28 August, 2003 by Melissa TrudingerAntisense Therapeutics has initiated its first Phase I clinical trial for antisense inhibitor ATL1102, which is being trialled as a treatment for multiple sclerosis.
Changes down on the pharm
28 August, 2003 by Graeme O'NeillThe age of molecular farming may be the salvation of many Australian farms.
Meditech results show decreasing losses
27 August, 2003 by Melissa TrudingerMeditech Research (ASX:MRL) has announced its half-year results, reporting a decreased loss of AUD$1.06 million after tax compared to the same period last year.
Prima swooped on by Peregrine
27 August, 2003 by Jeremy TorrInvestment bank Peregrine Corporate has upped its stake in Prima BioMed to around 14 per cent on the back of a AUD$7.2 million share placement of 11.62 million ordinary shares.
Investors boost Ventracor coffers by $33.5m
27 August, 2003 by Melissa TrudingerArtificial heart company Ventracor (ASX:VCR) has taken advantage of its market popularity to raise AUD$33.75 million in an unexpected placement to institutional and sophisticated investors in Australia, Europe and Asia.
Amrad posts end-of-year profit
26 August, 2003 by Melissa TrudingerIn a dramatic turnaround from last year's $14.4 million loss, Amrad (ASX:AML) has posted an inaugural after-tax profit of AUD$7.4 million for the 2002-2003 financial year, which includes $1.2 million operating profit in addition to the one-off profit realised from the sale of Amrad's Richmond property.
Metabolic brings in $12m through options
25 August, 2003 by Melissa TrudingerMetabolic Pharmaceuticals (ASX:MBP) is today heralding a recently finalised exercise of listed options had brought the company AUD$12 million.
EpiTan raises $7.4m in share placement
25 August, 2003 by Melissa TrudingerEpiTan (ASX:EPT) has raised nearly AUD$7.4 million in a share placement of 14.5 million shares priced at $0.51, providing cash reserves to see the company through to the end of 2004.
IDT posts record revenues
25 August, 2003 by Melissa TrudingerMelbourne-based drug development and manufacturing company Institute of Drug Technology Australia (ASX:IDT) has posted record revenues of AUD$25.8 million for the 2002-2003 financial year.
Benitec not likely to leave IMB: McKinley
22 August, 2003 by Jeremy TorrGene silencing specialist Benitec has denied rumours that it is to relocate from its IMB (Institute for Molecular Bioscience) base in Queensland to the US, claiming that North American media misreported the situation.
